

## **Ongoing Disclosure Notice**

# Disclosure of Directors and Senior Managers Relevant Interests

Number of financial products to which the transaction related:

| Sections 297(2) and 298(2), Financial Markets Conduct Act 2013  |  |  |  |
|---|--|--|--|
| To NZX Limited; and   |  |  |  |
| Name of listed issuer:  | Abano Healthcare Group Limited                                       |  |  |
| Date this disclosure made:  | 14 May 2018  |  |  |
| Date of last disclosure:  | 23 January 2018  |  |  |
|   |  |  |  |
| Director or senior manager giving disclosure  |  |  |  |
| Full name(s):   | Danny CHAN   |  |  |
| Name of listed issuer:  | Abano Healthcare Group Limited                                       |  |  |
| Name of related body corporate (if applicable):   | Not applicable   |  |  |
| Position held in listed issuer:   | Director   |  |  |
| Summary of acquisition or disposal of relevant interest (excluding specified derivative   | 201  |  |  |
| Class of affected quoted financial products:  |  |  |  |
| Nature of the affected relevant interest(s):  | Ordinary shares  |  |  |
| For that relevant interest-   | Registered holder & beneficial owner                                 |  |  |
| Number held in class before acquisition or disposal:  | 19,920 ordinary shares   |  |  |
| Number held in class after acquisition or disposal:   | 21,192 ordinary shares   |  |  |
| Current registered holder(s):   | Not applicable   |  |  |
| Registered holder(s) once transfers are registered:   | Danny CHAN   |  |  |
| . regional and regional data regional data.   | Daility Chan   |  |  |
| Summary of acquisition or disposal of specified derivatives relevant interest (if applic  | able)  |  |  |
| Type of affected derivative:  | Not applicable   |  |  |
| Class of underlying financial products:   | Not applicable   |  |  |
| Details of affected derivative-   |  |  |  |
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):   | Not applicable   |  |  |
| A statement as to whether the derivative is cash settled or physically settled:   | Not applicable   |  |  |
| Maturity date of the derivative (if any):   | Not applicable   |  |  |
| Expiry date of the derivative(if any):  | Not applicable   |  |  |
| The price specified in the terms of the derivative (if any):  | Not applicable   |  |  |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:                         | Not applicable   |  |  |
| For that derivative,-   |  |  |  |
| Parties to the derivative:  | Not applicable   |  |  |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  | Not applicable   |  |  |
| Details of transactions giving rise to acquisition or disposal  |  |  |  |
| Total number of transactions to which notice relates:   | One contract note  |  |  |
| Details of transactions requiring disclosure-   |  |  |  |
| Date of transaction:  | 8 May 2018   |  |  |
| Nature of transaction:  | On market purchase of shares pursuant to the<br>Directors Share Plan |  |  |
| Name of any other party or parties to the transaction (if known):   | Unknown  |  |  |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | \$10,805.64  |  |  |

1,272 ordinary shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Yes

Not required as acquired pursuant to the Directors Share Plan

Not applicable

#### Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

| Not applicable |  |  |
|----------------|--|--|
| Not applicable |  |  |

Not applicable
Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable Not applicable

Not applicable

#### Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

14 May 2018

Rachel Walsh Chief Financial Officer

### Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.